Industry News
Biotechnology Industry News
Rezolute’s stock has plunged 87%…
Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned approval application.
Eli Lilly has surpassed…
Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight loss and a 75.8% reduction in pain scores in patients with obesity and knee osteoarthritis. But
Moderna has tapped Swedish…
Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to four injectable therapies.
Barreling toward the end of its…
Barreling toward the end of its cash runway, GRI Bio has shared phase 2a data in idiopathic pulmonary fibrosis and made the case for further development of its potentially disease-modifying therapy.
OTR may still be keeping its own…
OTR may still be keeping its own pipeline under wraps, but Zealand has seen enough promise in the Chinese biotech’s platform to agree to hand over up to $30 million in upfront payments.
Two affiliates of Apple Tree…
Two affiliates of Apple Tree Partners have filed for bankruptcy, a move designed to continue funding the venture firm's portfolio biotechs as a funding dispute with a top investor plays out.
Rival European pharma giants…
Rival European pharma giants Sanofi and GSK have both forged new partnerships to bolster their preclinical research. Paris-based Sanofi is investing in a U.S. biotech’s autoimmune research, while GSK has tapped a fellow British outfit
Formation Bio is inking a deal…
Formation Bio is inking a deal worth more than $600 million in biobucks for ex-China rights to a next-gen immunology asset from Lynk Pharmaceuticals.
Roche has lifted the lid on the…
Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor degrader to a 30% reduction in the risk of invasive disease recurrence or death.
A Chinese biotech helmed by an…
A Chinese biotech helmed by an AstraZeneca veteran has secured $108 million in series B funds, which the company will use to advance its lead KRAS inhibitor into phase 3 studies.
People come to Orlando to escape….
People come to Orlando to escape. With Disney World, SeaWorld and Universal Studios all in the area, there are endless opportunities to leave behind the challenges of the real world for a bit of relaxation
Exicure’s investigational small…
Exicure’s investigational small molecule succeeded in mobilizing key blood-forming cells in almost 90% of patients in a phase 2 multiple myeloma trial, paving the way for smoother and more effective autologous stem cell transplants.
Ose Immunotherapeutics is…
Ose Immunotherapeutics is prioritizing its lung cancer med Tedopi and its ulcerative colitis therapy lusvertikimab.
Pfizer’s recent bidding war for…
Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by this morning’s $1.9 billion biobucks deal.
The FDA is raising the bar for…
The FDA is raising the bar for approval of CAR T-cell therapies in oncology. Under plans outlined by the FDA’s biologics chief Vinay Prasad, M.D., the agency will require developers of many CAR-Ts to show
Novartis has tapped an AI-enabled…
Novartis has tapped an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for immuno-dermatology conditions.
GSK is walking away from Ideaya…
GSK is walking away from Ideaya Biosciences after a five-year-long partnership that initially focused on three of Ideaya's synthetic lethality programs.
Patients with polycythemia vera, a…
Patients with polycythemia vera, a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. But the tide may finally be turning in their favor, as Merck
The drug “has the potential to…
The drug “has the potential to transform the care of those living with DMD amenable to exon 51 skipping,” Dyne CEO John Cox said in a statement.
Dr. Reddy’s Laboratories is…
Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain territories while leaving the Australian biotech with ownership in key markets.